This observation suggested that the addition of xevinapant to CRT reversed the CD8+ T-cell dependency of tumor control either by reducing the numbers of CD8+ TILs (Fig. 1E) or by rendering the remaining CD8+ TILs ineffectual. Here, CD8A is linked to neoplasm.